AZD9291

AZD9291, also known as Osimertinib, is a targeted cancer therapy used primarily for treating lung cancer. It specifically targets a mutation in the EGFR gene found in some patients with non-small cell lung cancer (NSCLC), which is a common type of lung cancer. By blocking the activity of this mutated protein, AZD9291 helps to stop cancer cells from growing and spreading. It is often used for patients who have developed resistance to other treatments, showing promise in improving survival rates and reducing side effects compared to traditional chemotherapy.